Our mission to shape the cell and gene therapy landscape in India is actively underway - with more than 150 infusions of NexCAR19 (Talicabtagene autoleucel) now having been administered across dozens of haemato-oncology treating hospitals across the country. We are constantly engaging with the oncology community in ensuring that CAR-T cell therapies are accessible, affordable, and a viable treatment option in the management of refractory/relapsing B-cell Precursor Acute Lymphoblastic Leukaemia and B-cell Lymphomas in patients aged 15 years and above.
ImmunoACT
Biotechnology Research
Navi Mumbai, Maharashtra 18,515 followers
India's Leader in Cell & Gene Therapies
About us
Spun-out from IIT-Bombay in 2018, ImmunoACT is India's pioneer in the development of the country's first indigenous Cell & Gene Therapy. With a rapidly expanding pipeline beginning with blood cancers, our mission is to provide affordable access to novel autologous CAR-T cell therapies.
- Website
-
http://ImmunoACT.com
External link for ImmunoACT
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Navi Mumbai, Maharashtra
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Cell & Gene Therapies, Translational Research, and Viral Vector Process Development & Manufacturing
Locations
-
Primary
Get directions
ImmunoACT, 1st Floor, R-977
T.T.C. Industrial Area, MIDC Rabale
Navi Mumbai, Maharashtra 400701, IN
Employees at ImmunoACT
-
Shreewardhan Rajopadhye, PhD
Upstream Process Development & Manufacturing Scientist | CGTs & Biologics | Discovery to Clinic to Commerical
-
Ashish Saroha, PhD
Research Scientist/Oncology/Cell and gene therapy/ CAR-T Cell manufacturing and R&D / immunotherapy/glycobiology/proteomics
-
Ankush Korishettar
Making immunotherapies affordable and accessible to all
-
Kalyani Dalal
Scientist I at ImmunoACT
Updates
-
We're excited to collaborate with SPARSH Hospital, Bengaluru to provide access to our Gene-modified cell therapies, beginning with NexCAR19 (Talicabtagene autoleucel), India's first CAR-T cell therapy approved for the treatment of relapsed/refractory B-cell Lymphomas and B-Acute Lymphoblastic Leukaemia in patients aged 15 and above.
-
-
ImmunoACT and Gleneagles BGS Hospital, Bengaluru intend to collaborate in providing access to potentially life-saving CAR-T cell therapies beginning with NexCAR19 (Talicabtagene autoleucel) for the treatment of r/r B-cell lymphoma and B-cell precursor acute lymphoblastic leukaemia. This marks another step in ImmunoACT's mission to provide equitable and affordable access to innovative CAR-T cell therapies to serve patients across India and beyond. Rahul Purwar Shirish Arya Dr. Ashutosh Tripathi Dr. Nirali Solanke Chandan Akhilesh Kumar Pandey Karan Gera Dr Rajeev Vijayakumar Dr Prerana Nasregi Dr. Kiran Kumar Sajjanshetty
-
-
We are pleased to announce a collaboration with TATA MEDICAL CENTER, Kolkata in our endeavour to expand access to NexCAR19 (Talicabtagene autoleucel) for refractory/relapsing B-cell malignancies and for our future CAR-T cell therapies. Through Tata Medical Center's role as a leader in affordable and accessible, advanced cancer care in East India, our mission to improve the paradigm of treatment of aggressive cancers with our innovative gene-modified cell therapies is one step closer.
-
-
We’re #hiring ! Our team is expanding. To be a part of our journey, email your CV jobs@immunoact.com Please share your details - https://lnkd.in/dfWdWktc We’re excited to connect with you!
-
We’re #hiring ! Our team is expanding. To be a part of our journey, email your CV jobs@immunoact.com Please share your details - https://lnkd.in/dfWdWktc We’re excited to connect with you!
-
We recently visited Apollo Multispeciality Hospitals, Kolkata, our first partnered hospital in West Bengal and a gateway to the East of India. We look forward to improved access across patients in the region for the NexCAR19, our CD19-directed, humanized CAR-T cell therapy approved for treatment of patients with r/r B-cell lymphoma and B-cell precursor acute lymphoblastic leukaemia. Thanks to the Apollo Kolkata team for their hospitality.
-
-
Dr. Madhav Danthala (Consultant Medical Oncology, Haemato-oncology, and Bone Marrow Transplant - Yashoda Hospitals) talks about the promise of CAR-T cell therapy and its landscape in India, along with a walkthrough of the entire treatment cycle and patient's journey. He also highlights NexCAR19, India's first approved CD19-directed CAR-T cell therapy for refractory/relapsed B-cell lymphomas and B-cell precursor acute lymphoblastic leukaemia in patients aged 15 and above. Watch the video in the link below! https://lnkd.in/giiv7kf9
Revolutionizing Cancer Treatment in India: The Promise of CAR T-Cell Therapy
https://www.youtube.com/
-
Remember to register for our webinar "Post-infusion management of CAR-toxicities in a real-world setting" led by Dr. Esha Kaul, which is tomorrow (May 28) at 8:00 PM IST!
We are pleased to announce Session 6 of the NexCAR19 Webinar Series. This session, titled, "Post-infusion management of CAR-toxicities in a real-world setting" will be led by Dr. Esha Kaul (Director - Haematology, Haemato-Oncology, & BMT at Max Super Speciality Hospital, Vaishali). It will cover various aspects involved in managing haematological & non-haematological effects typically seen post-infusion with CD19-directed CAR-T cell therapies, and their landscape beyond clinical trials. Register for this webinar on the link below to receive access!
This content isn’t available here
Access this content and more in the LinkedIn app
-
We’re #hiring ! Our team is expanding. To be a part of our journey, email your CV and details to jobs@immunoact.com Also share your details on https://lnkd.in/dfWdWktc We’re excited to connect with you!
-